Japanese Takeda to acquire Shire for $62bn
08-05-2018
Actavis and Zydus settle with Supernus over seizure drug
13-03-2017
11-06-2018
AVNphotolab / iStockphoto.com
The US Federal Trade Commission (FTC) has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FTC, Federal Trade Commission, Takeda Pharmaceuticals, Hatch-Waxman Act, Zydus Pharmaceuticals, patent, patent infringement